Status:
COMPLETED
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
Kenya Medical Research Institute
Conditions:
HIV
Malaria
Eligibility:
All Genders
15+ years
Phase:
PHASE4
Brief Summary
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) \[CTX\] proph...
Detailed Description
We conducted this study in Kisumu, Kenya where HIV prevalence is high and malaria is highly endemic. HIV infected and uninfected adults were assigned to receive daily CTX if CD4 cell count was \<350, ...
Eligibility Criteria
Inclusion
- Clients presenting to the CRC HIV counseling and testing site in Kisumu were eligible for the study if they met the following inclusion criteria:
- 15 years of age or older
- Able to make all follow-up visits (i.e. do not plan to leave Kisumu during the next 6 months, are not homebound)
- Able to understand and give informed consent.
Exclusion
- Clients were not eligible for the study if they met any of the following exclusion criteria:
- Known allergic reaction to sulfa medications (i.e. CTX, sulfadoxine- pyrimethamine)
- Women in their first trimester of pregnancy or planning to become pregnant in the next 6 months
- Clients taking daily antibiotics for treatment of a chronic illness; or prophylaxis, excluding tuberculosis treatment.
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
End Date :
November 1 2003
Estimated Enrollment :
1478 Patients enrolled
Trial Details
Trial ID
NCT00137657
Start Date
February 1 2002
End Date
November 1 2003
Last Update
December 13 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CDC KEMRI Research Institute
Kisumu, Kenya